Cardiac Transplantation

Researchers have developed a first-in-class antibody-drug conjugate targeting High Endothelial Venules via the CHST4 enzyme. This therapy promotes regulatory T cell induction and long-term heart transplant survival in murine models using significantly lower systemic drug doses.